Equities Analysts Offer Predictions for Sarepta Therapeutics, Inc.’s Q1 2026 Earnings (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities research analysts at Zacks Research cut their Q1 2026 earnings per share (EPS) estimates for Sarepta Therapeutics in a note issued to investors on Tuesday, September 17th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn $2.75 per share for the quarter, down from their previous estimate of $2.77. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $1.47 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q2 2026 earnings at $3.20 EPS and FY2026 earnings at $12.43 EPS.

Several other equities analysts have also recently weighed in on SRPT. Barclays lowered their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Bank of America increased their price objective on Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a research note on Friday, June 21st. Evercore ISI raised Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and lowered their target price for the company from $185.00 to $179.00 in a research note on Thursday, August 8th. Finally, BMO Capital Markets increased their price target on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a research report on Monday, June 24th. Three equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $187.39.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $127.10 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The company has a market cap of $12.01 billion, a P/E ratio of 1,155.45 and a beta of 0.81. Sarepta Therapeutics has a fifty-two week low of $55.25 and a fifty-two week high of $173.25. The firm’s 50 day simple moving average is $138.26 and its 200-day simple moving average is $132.61.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. During the same period in the previous year, the firm earned ($0.27) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 38.9% compared to the same quarter last year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the sale, the insider now directly owns 21,261 shares in the company, valued at $3,467,243.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the transaction, the insider now owns 21,261 shares of the company’s stock, valued at approximately $3,467,243.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael Andrew Chambers bought 37,038 shares of the stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the acquisition, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. The disclosure for this purchase can be found here. Insiders have sold a total of 52,801 shares of company stock worth $8,399,586 over the last 90 days. Insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Several large investors have recently bought and sold shares of the stock. Capital International Investors increased its holdings in shares of Sarepta Therapeutics by 160.0% during the 4th quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock worth $457,221,000 after purchasing an additional 2,917,797 shares during the period. Farallon Capital Management LLC grew its position in Sarepta Therapeutics by 102.8% during the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after buying an additional 1,243,427 shares in the last quarter. Norges Bank bought a new position in Sarepta Therapeutics during the fourth quarter valued at about $80,697,000. Bank of Nova Scotia acquired a new position in Sarepta Therapeutics in the 4th quarter valued at approximately $50,990,000. Finally, Avoro Capital Advisors LLC lifted its position in shares of Sarepta Therapeutics by 7.9% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after acquiring an additional 319,444 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.